Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Release

 View printer-friendly version

Charles River Laboratories Changes the Date of Its Third-Quarter 2017 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 12, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL) has changed the date of its third-quarter 2017 earnings release and conference call. The Company will now release financial results on Thursday, November 9th, before the market opens. The conference call to discuss this information will be held on Thursday, November 9th, at 8:30 a.m. ET.

Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Source: Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.
Investor Relations Contact:
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com

Featured Report

2018 Annual Report (PDF)

Investor Hotline

877-567-6CRL (6275)